Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines. Vrije Universiteit Brussel
year survival of 20%. While targeted therapies such as PARP
inhibitors have improved progression free survival, immunotherapy
has so far not resulted in clear patient benefit. Importantly, the role of
tumor-dendritic cells (DCs) as a key player in mounting an adaptive
immune response has not been investigated yet in OC. Indeed, our
lab ...